inflammation

TWiV 874: COVID-19 clinical update #105 with Dr. Daniel Griffin

In COVID-19 clinical update #105, Daniel Griffin discusses changes in brain structure after infection, dementia in patients with pneumonia, Paxlovid in children, mask effectiveness in schools, host factors and severe disease, post-acute symptoms, and the mission of CEPI. Click arrow to playDownload TWiV 874 (49 MB .mp3, 41 min)Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Show notes …

TWiV 874: COVID-19 clinical update #105 with Dr. Daniel Griffin Read More »

TWiV 872: COVID-19 clinical update #104 with Dr. Daniel Griffin

In COVID-19 clinical update #104, Daniel Griffin reviews effectiveness of mRNA vaccines among children, number of children affected by disease, accuracy of rapid antigen tests, CDC guidance for prevention strategies, monoclonal antibody effectiveness, predicting progression to severe respiratory failure from pneumonia, risk of long COVID after two vaccine doses, and peripheral neuropathy in long COVID.

TWiV 870: COVID-19 clinical update #103 with Dr. Daniel Griffin

In COVID-19 clinical update #103, Daniel Griffin covers immunocompromised people, hospitalization of children, vaccine usage update, Omicron and cross-reactive neutralizing antibodies, reinfection prevents disease in hamsters, repeated infections with endemic coronaviruses, global burden of antimicrobial resistance, ivermectin not protective in hamsters, and Omicron evades therapeutic monoclonals. Click arrow to playDownload TWiV 870 (52 MB .mp3, 43 …

TWiV 870: COVID-19 clinical update #103 with Dr. Daniel Griffin Read More »

TWiV 868: COVID-19 clinical update #102 with Dr. Daniel Griffin

In COVID-19 clinical update #102, Daniel Griffin reviews children and COVID, effectiveness of maternal vaccination, vaccines for immunocompromised, primary care physicians and vaccination rates, booster safety among adults, placentitis, azithromycin, oral Nirmatrelvir, Omicron antibody evasion, EUA for bebtelovimab, IL-1 blocking agents, thromboprophylaxis, effectiveness of vaccines against long COVID, and risks of mental health outcomes.

TWiV 867: I love the smell of vaccines in the morning

TWiV reviews an experimental, intranasally administered SARS-CoV-2 vaccine that utilizes adenovirus vectors to deliver three viral proteins and induces immunity to ancestral and variant isolates. Hosts: Vincent Racaniello, Alan Dove, Rich Condit, and Kathy Spindler Click arrow to playDownload TWiV 867 (128 MB .mp3, 107 min)Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Show notes at microbe.tv/twiv

Scroll to Top